(3Ez,5s)-5-[(4-hydroxy-1-piperidinyl)carbonyl]-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-3-pyrrolidinone o-methyloxime

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3Ez,5s)-5-[(4-hydroxy-1-piperidinyl)carbonyl]-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-3-pyrrolidinone o-methyloxime
• 英文别名: (4-hydroxypiperidin-1-yl)-[(2S)-4-methoxyimino-1-[4-(2-methylphenyl)benzoyl]pyrrolidin-2-yl]methanone
• 化学式: C₂₅H₂₉N₃O₄
• 分子量: 435.5
• InChiKey: LGIGYOAMFFZLTQ-QHCPKHFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  82.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  (4EZ)-1-(tert-butoxycarbonyl)-4-(methoxyimino)-L-proline 、 2’-甲基联苯-4-甲酸 、 4-羟基哌啶 以the title compound was obtained in 86% purity by HPLC的产率得到(3Ez,5s)-5-[(4-hydroxy-1-piperidinyl)carbonyl]-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-3-pyrrolidinone o-methyloxime
  参考文献：
  名称：

  Pharmaceutically active pyrrolidine derivatives

  摘要：

  本发明涉及式(I)的吡咯烷衍生物。所述化合物优选用作药物活性化合物。具体而言，式(I)的吡咯烷衍生物在治疗和/或预防早产、早产和痛经方面是有用的。特别地，本发明涉及显示出 oxytocin 受体的显著调节作用，特别是拮抗剂活性的吡咯烷衍生物。更优选地，所述化合物在治疗和/或预防由 oxytocin 介导的疾病状态，包括早产、早产和痛经方面是有用的。本发明还涉及新的吡咯烷衍生物以及它们的制备方法，其中 X 从 CR6R7、NOR6、NNR6R7 组中选择；A 从 —(C═O)—、—(C═O)—O—、—C(═NH)—、—(C═O)—NH—、—(C═S)—NH、—SO22-、—SO2NH—、—CH2- 组中选择；B 要么是一个 —(C═O)—NR8R9 组，要么表示具有式(a)的杂环残基，其中 Q 是 NR10、O 或 S；n 是选择的整数 0、1 或 2；Y、Z 和 E 与它们附着的 2 个碳一起形成一个 5-6 个成员的芳基或杂芳基环。

  公开号：

  US07211601B2

文献信息

• Pharmaceutically active pyrrolidine derivatives as bax inhibitors
  申请人：——

  公开号：US20030171309A1

  公开（公告）日：2003-09-11

  The present invention is related to new substituted pyrrolidine derivatives of formula (I). Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of neurodegenerative disorders, diseases associated with polygultamine tracts, epilepsy, ischemia, infertility, cardiovascular disorders renal hypoxia, hepatitis and AIDS. Said pyrrolidine derivatives display a modulatory and most notably a down-regulating-up to an inhibitory-activity with respect to the cellular death agonist Bax and/or the activation pathways leading to Bax and allows therefore to block the release of cytochrome (c). The present invention is furthermore related to novel pharmaceutically activity substituted pyrrolidine derivatives as well as to methods of their preparation, wherein X is selected from the group consisting of O, S, CR<6>R<7>, NOR<6>, NNR<6>R<7>; A is selected from the group consisting of —(C═O)—, —(C═O)—O—, —C(═NH)—, —(C═O)—NH—, —(C═S)—NH, —SO2-, —SO2NH—; —CH2-; B is either a group —(C═O)—NR<8>R<9> or represents a heterocyclic residue having the formula (II) wherein Q is NR<10>, O or S; n is an integer selected of 0, 1 or 2; Y, Z and E form together with the 2 carbons to which they are attached a 5-6 membered aryl or heteroaryl ring.

  本发明涉及新的取代吡咯烷衍生物的化学式(I)。所述化合物通常用作药用活性化合物。具体来说，化学式(I)的吡咯烷衍生物在治疗和/或预防神经退行性疾病、与多谷氨酸氨基酸序列相关的疾病、癫痫、缺血、不孕症、心血管疾病、肾脏缺氧、肝炎和艾滋病方面具有用处。所述吡咯烷衍生物显示出对细胞死亡促进子Bax和/或导致Bax激活途径的调节作用，最显著地是下调至抑制活性，并因此允许阻止细胞色素(c)的释放。本发明还涉及新的具有药用活性的取代吡咯烷衍生物，以及它们的制备方法，其中X选自O、S、CR<6>R<7>、NOR<6>、NNR<6>R<7>组成的群；A选自—(C═O)—、—(C═O)—O—、—C(═NH)—、—(C═O)—NH—、—(C═S)—NH、—SO2-、—SO2NH—；—CH2-；B是一个群—(C═O)—NR<8>R<9>或代表具有化学式(II)的杂环残基，其中Q是NR<10>、O或S；n是选自0、1或2的整数；Y、Z和E与它们连接的两个碳共同形成一个5-6成员芳香族或杂芳族环。
• [EN] PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS<br/>[FR] DERIVES PYRROLIDINE ACTIFS SUR LE PLAN PHARMACEUTIQUE UTILISES EN TANT QU'INHIBITEURS DE BAX
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2001072705A1

  公开（公告）日：2001-10-04

  The present invention is related to pyrrolidine derivatives of formula (I). Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to pyrrolidine derivatives displaying a substantial modulatory, notably an antagonist activity of the oxytocin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin, including premature labor, premature birth and dysmenorrhea. The present invention is furthermore related to novel pyrrolidine derivatives as well as to methods of their preparation, wherein X is selected from the group consisting of CR?6R7, NOR6, NNR6R7¿; A is selected from the group consisting of -(C=O)-, -(C=O)-O-, -C(=NH)-, -(C=O)-NH-, -(C=S)-NH, -SO¿2?2-, -SO2NH-, -CH2-,B is either a group -(C=O)-NR?8R9¿ or represents a heterocyclic residue having the formula (a) wherein Q is NR10, O or S; n is an integer selected of 0, 1 or 2; Y, Z and E form together with the 2 carbons to which they are attached a 5-6 membered aryl or heteroaryl ring.

  本发明涉及式（I）的吡咯烷衍生物。所述化合物最好用作药物活性化合物。具体而言，式（I）的吡咯烷衍生物在治疗和/或预防早产、早产和痛经方面是有用的。特别是，本发明涉及显示氧合胃素受体重要调节作用，特别是拮抗剂活性的吡咯烷衍生物。更具体地说，所述化合物在治疗和/或预防由氧合胃素介导的疾病状态方面是有用的，包括早产、早产和痛经。本发明还涉及新的吡咯烷衍生物以及其制备方法，其中X选自CR？6R7，NOR6，NNR6R7¿组成的群；A选自-(C=O)-，-(C=O)-O-，-C（=NH）-，-(C=O)-NH-，-(C=S)-NH，-SO¿2？2-，-SO2NH-，-CH2-；B是-(C=O)-NR？8R9¿或表示具有公式（a）的杂环残基，其中Q是NR10，O或S；n是选择的整数0、1或2；Y、Z和E与它们附着的2个碳原子一起形成一个5-6成员芳香族或杂芳基环。
• PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS
  申请人：Applied Research Systems ARS Holding N.V.

  公开号：EP1268418B1

  公开（公告）日：2006-06-14
• PYRROLIDINE DERIVATIVES USEFUL AS BAX INHIBITORS
  申请人：Applied Research Systems ARS Holding N.V.

  公开号：EP1268419A1

  公开（公告）日：2003-01-02
• US7211601B2
  申请人：——

  公开号：US7211601B2

  公开（公告）日：2007-05-01